Meningococcal disease is an acute
infection caused by the gram-negative bacterium Neisseria meningitidis. Its
rapid onset and severity of symptoms makes prompt and effective diagnosis and
treatment nearly impossible. For these reasons the meningococcal disease space
is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as
Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global
sales, with the US adolescent market being the key target segment.
GlobalData expects growth in the
meningococcal vaccines market to be primarily driven by the launch of serotype
B vaccines, which address a critical unmet need in the treatment landscape.
Vaccines that better protect infants and/or provide a longer duration of
immunity also have an opportunity to seize market share during 2012-2022.
To
Read The Complete Report with TOC : http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-global-drug-forecast-and-market-analysis-to-2022
Scope
- Overview of meningococcal
disease, including epidemiology, etiology, general symptoms from
infection, and national vaccination recommendations and guidelines.
- Annualized meningococcal
vaccine market revenue, annual cost of vaccination and treatment usage
pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include
strategic competitor assessment, market characterization, unmet needs,
clinical trial mapping and implications for the meningococcal vaccine
market.
- Pipeline analysis:
comprehensive data split across different phases and emerging trends,
specifically serotype B vaccines and early stage infant and pentavalent
vaccines.
- Analysis of the current and
future market competition in the global meningococcal vaccine market.
Insightful review of the key industry and governmental drivers, restraints
and challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Market Model Features
An interactive excel forecast model
based on primary research interviews and surveys with KOLs and high-prescribing
physicians is included in this report*. This patient based model provides
diagnosis rates, patient segmentation, treatment rates, annual costs of therapy
, and indication-specific drug sales for the 10 year forecast period. The
forecast model is robust, fully transparent, and easy to navigate. Moreover,
our models support data presented in the reports and the complete methodology
is outlined in the report and the model.
*Model only available with site and
global license purchases.
Key Findings
- Country-specific epidemiology
and serotype distributions heavily influence immunization recommendations
and vaccine usage.
- Serotype B vaccines are
expected to drive growth of the market space during the forecast period.
- Major players will leverage
their R&D, manufacturing, and distribution networks to maintain their
stakes in the market.
- Government endorsements of new
and existing vaccines are anticipated to dramatically influence market
growth.
Key Questions Answered in this
Report
- How large an impact will
serotype B vaccines have on the meningococcal market? What do key opinion
leaders think of these vaccines?
- What are the key vaccines for
each age segment and country?
- Which meningococcal vaccines
will face adoption challenges in the market? What is the projected uptake
of new vaccines, such as Novartis’ Bexsero, over the forecast period?
- The developmental pipeline
consists of vaccines that address serotype B protection and immunogenicity
in infants. Which of these vaccines will attain high sales revenues during
2012-2022 and in which markets?
- What governmental and industry
developments are likely to affect the vaccination rates in the markets
researched? Which is the largest growth market globally?
Key Benefits
- Develop and design your
in-licensing and out-licensing strategies through a review of pipeline
products and technologies, and by identifying the companies with the most
robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the meningococcal vaccine
market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market segments, and
companies likely to impact the global meningococcal vaccine market in
future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and by
analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
meningococcal vaccine market from 2012-2022.
- Organize your sales and
marketing efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and
strategic partnerships.
About
Us
MarketResearchReports.Biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription
access and consulting services. We serve all sizes and types of companies
spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
sal� K a k � � hreports.biz">sales@marketresearchreports.biz
No comments:
Post a Comment